Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Up 2.8% – What’s Next?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares rose 2.8% on Wednesday . The stock traded as high as $30.00 and last traded at $29.97. Approximately 25,883 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 368,973 shares. The stock had previously closed at $29.14.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Friday. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday. Finally, Piper Sandler reissued a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.80.

Collegium Pharmaceutical Price Performance

The company has a market cap of $1.06 billion, a PE ratio of 14.19 and a beta of 0.82. The business’s 50 day moving average price is $30.57 and its 200-day moving average price is $34.04. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its position in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares during the last quarter. CWM LLC increased its holdings in Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares during the last quarter. TD Private Client Wealth LLC raised its stake in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares in the last quarter. Virtus Fund Advisers LLC bought a new position in Collegium Pharmaceutical during the 3rd quarter worth approximately $72,000. Finally, AXA S.A. acquired a new position in shares of Collegium Pharmaceutical in the 2nd quarter worth approximately $209,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.